Literature DB >> 26939910

Altering the course of schizophrenia: progress and perspectives.

Mark J Millan1, Annie Andrieux2, George Bartzokis3, Kristin Cadenhead4, Paola Dazzan5, Paolo Fusar-Poli5, Jürgen Gallinat6, Jay Giedd7, Dennis R Grayson8, Markus Heinrichs9, René Kahn10, Marie-Odile Krebs11, Marion Leboyer12, David Lewis13, Oscar Marin14, Philippe Marin15, Andreas Meyer-Lindenberg16, Patrick McGorry17, Philip McGuire18, Michael J Owen19, Paul Patterson20, Akira Sawa21, Michael Spedding22, Peter Uhlhaas20, Flora Vaccarino23, Claes Wahlestedt24, Daniel Weinberger25.   

Abstract

Despite a lack of recent progress in the treatment of schizophrenia, our understanding of its genetic and environmental causes has considerably improved, and their relationship to aberrant patterns of neurodevelopment has become clearer. This raises the possibility that 'disease-modifying' strategies could alter the course to - and of - this debilitating disorder, rather than simply alleviating symptoms. A promising window for course-altering intervention is around the time of the first episode of psychosis, especially in young people at risk of transition to schizophrenia. Indeed, studies performed in both individuals at risk of developing schizophrenia and rodent models for schizophrenia suggest that pre-diagnostic pharmacotherapy and psychosocial or cognitive-behavioural interventions can delay or moderate the emergence of psychosis. Of particular interest are 'hybrid' strategies that both relieve presenting symptoms and reduce the risk of transition to schizophrenia or another psychiatric disorder. This Review aims to provide a broad-based consideration of the challenges and opportunities inherent in efforts to alter the course of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26939910     DOI: 10.1038/nrd.2016.28

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  314 in total

1.  Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits.

Authors:  Guomei Tang; Kathryn Gudsnuk; Sheng-Han Kuo; Marisa L Cotrina; Gorazd Rosoklija; Alexander Sosunov; Mark S Sonders; Ellen Kanter; Candace Castagna; Ai Yamamoto; Zhenyu Yue; Ottavio Arancio; Bradley S Peterson; Frances Champagne; Andrew J Dwork; James Goldman; David Sulzer
Journal:  Neuron       Date:  2014-08-21       Impact factor: 17.173

Review 2.  Is adolescence a sensitive period for sociocultural processing?

Authors:  Sarah-Jayne Blakemore; Kathryn L Mills
Journal:  Annu Rev Psychol       Date:  2013-09-06       Impact factor: 24.137

Review 3.  5-HT6 Receptor Antagonists: Potential Efficacy for the Treatment of Cognitive Impairment in Schizophrenia.

Authors:  Natasja M W J de Bruin; Chris G Kruse
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 4.  Using human brain imaging studies as a guide toward animal models of schizophrenia.

Authors:  S S Bolkan; F Carvalho Poyraz; C Kellendonk
Journal:  Neuroscience       Date:  2015-05-30       Impact factor: 3.590

5.  Increased stress-induced dopamine release in psychosis.

Authors:  Romina Mizrahi; Jean Addington; Pablo M Rusjan; Ivonne Suridjan; Alvina Ng; Isabelle Boileau; Jens C Pruessner; Gary Remington; Sylvain Houle; Alan A Wilson
Journal:  Biol Psychiatry       Date:  2011-11-30       Impact factor: 13.382

6.  Adolescent stress-induced epigenetic control of dopaminergic neurons via glucocorticoids.

Authors:  Minae Niwa; Hanna Jaaro-Peled; Stephanie Tankou; Saurav Seshadri; Takatoshi Hikida; Yurie Matsumoto; Nicola G Cascella; Shin-ichi Kano; Norio Ozaki; Toshitaka Nabeshima; Akira Sawa
Journal:  Science       Date:  2013-01-18       Impact factor: 47.728

Review 7.  Dysconnectivity, large-scale networks and neuronal dynamics in schizophrenia.

Authors:  Peter J Uhlhaas
Journal:  Curr Opin Neurobiol       Date:  2012-12-07       Impact factor: 6.627

8.  Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome.

Authors:  Patrick D McGorry; Barnaby Nelson; Lisa J Phillips; Hok Pan Yuen; Shona M Francey; Annette Thampi; Gregor E Berger; G Paul Amminger; Magenta B Simmons; Daniel Kelly; Grad Dip; Andrew D Thompson; Alison R Yung
Journal:  J Clin Psychiatry       Date:  2012-11-27       Impact factor: 4.384

9.  Improving emotional face perception in autism with diuretic bumetanide: a proof-of-concept behavioral and functional brain imaging pilot study.

Authors:  Nouchine Hadjikhani; Nicole R Zürcher; Ophelie Rogier; Torsten Ruest; Loyse Hippolyte; Yehezkel Ben-Ari; Eric Lemonnier
Journal:  Autism       Date:  2013-12-16

Review 10.  Schizophrenia and the gut-brain axis.

Authors:  Katlyn Nemani; Reza Hosseini Ghomi; Beth McCormick; Xiaoduo Fan
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2014-09-19       Impact factor: 5.067

View more
  141 in total

1.  Lack of evidence to favor specific preventive interventions in psychosis: a network meta-analysis.

Authors:  Cathy Davies; Andrea Cipriani; John P A Ioannidis; Joaquim Radua; Daniel Stahl; Umberto Provenzani; Philip McGuire; Paolo Fusar-Poli
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

Review 2.  Neuroimaging markers of antipsychotic treatment response in schizophrenia: An overview of magnetic resonance imaging studies.

Authors:  Goda Tarcijonas; Deepak K Sarpal
Journal:  Neurobiol Dis       Date:  2018-06-25       Impact factor: 5.996

3.  Regional Heterogeneity in Gene Expression, Regulation, and Coherence in the Frontal Cortex and Hippocampus across Development and Schizophrenia.

Authors:  Leonardo Collado-Torres; Emily E Burke; Amy Peterson; JooHeon Shin; Richard E Straub; Anandita Rajpurohit; Stephen A Semick; William S Ulrich; Amanda J Price; Cristian Valencia; Ran Tao; Amy Deep-Soboslay; Thomas M Hyde; Joel E Kleinman; Daniel R Weinberger; Andrew E Jaffe
Journal:  Neuron       Date:  2019-06-04       Impact factor: 17.173

Review 4.  Modeling schizophrenia pathogenesis using patient-derived induced pluripotent stem cells (iPSCs).

Authors:  Haneul Noh; Zhicheng Shao; Joseph T Coyle; Sangmi Chung
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-06-28       Impact factor: 5.187

Review 5.  Unraveling the genetic architecture of copy number variants associated with schizophrenia and other neuropsychiatric disorders.

Authors:  Timothy P Rutkowski; Jason P Schroeder; Georgette M Gafford; Stephen T Warren; David Weinshenker; Tamara Caspary; Jennifer G Mulle
Journal:  J Neurosci Res       Date:  2016-11-08       Impact factor: 4.164

6.  Developmental timing and critical windows for the treatment of psychiatric disorders.

Authors:  Oscar Marín
Journal:  Nat Med       Date:  2016-10-26       Impact factor: 53.440

7.  What Is an Attenuated Psychotic Symptom? On the Importance of the Context.

Authors:  Paolo Fusar-Poli; Andrea Raballo; Josef Parnas
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

8.  Connectome-Based Patterns of First-Episode Medication-Naïve Patients With Schizophrenia.

Authors:  Long-Biao Cui; Yongbin Wei; Yi-Bin Xi; Alessandra Griffa; Siemon C De Lange; René S Kahn; Hong Yin; Martijn P Van den Heuvel
Journal:  Schizophr Bull       Date:  2019-10-24       Impact factor: 9.306

Review 9.  [Genuine motor phenomena in schizophrenia : Neuronal correlates and pathomechanisms].

Authors:  D Hirjak; G Northoff; P A Thomann; K M Kubera; R C Wolf
Journal:  Nervenarzt       Date:  2018-01       Impact factor: 1.214

10.  [The CIMH track concept in the treatment of psychotic disorders].

Authors:  Dusan Hirjak; Peter Gass; Michael Deuschle; F Markus Leweke; Andreas Böhringer; Nadine Schenkel; Doris Borgwedel; Marco Heser; Antje Breisacher; Andreas Meyer-Lindenberg
Journal:  Nervenarzt       Date:  2020-03       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.